Aravive Forecasted Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Aravive.
Key information
19.8%
Earnings growth rate
31.7%
EPS growth rate
Biotechs earnings growth | 16.4% |
Revenue growth rate | -32.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 22 Aug 2023 |
Recent future growth updates
Recent updates
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Apr 26Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Sep 03Aravive Q2 GAAP EPS misses, revenue beats
Aug 11Aravive appoints Robert Geller as CMO
Jul 05We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully
May 15Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Nov 06Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Jun 25Aravive EPS beats by $0.01, misses on revenue
May 06Aravive shares rise after dosing first patient in late-stage ovarian cancer study
Apr 27Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?
Mar 18Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Feb 09Aravive: Pipeline-In-A-Pill In Oncology
Dec 28Aravive (ARAV) Investor Presentation - Slideshow
Dec 04Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative
Nov 19Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China
Nov 10Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 1 | -24 | -5 | 8 | 3 |
12/31/2024 | 2 | -23 | N/A | 7 | 3 |
12/31/2023 | 4 | -70 | N/A | -41 | 3 |
6/30/2023 | 9 | -77 | -69 | -69 | N/A |
3/31/2023 | 10 | -113 | -70 | -70 | N/A |
12/31/2022 | 9 | -76 | -65 | -65 | N/A |
9/30/2022 | 9 | -60 | -59 | -59 | N/A |
6/30/2022 | 6 | -56 | -49 | -49 | N/A |
3/31/2022 | 8 | -44 | -35 | -35 | N/A |
12/31/2021 | 7 | -39 | -32 | -32 | N/A |
9/30/2021 | 12 | -30 | -20 | -20 | N/A |
6/30/2021 | 10 | -30 | -17 | -17 | N/A |
3/31/2021 | 6 | -28 | -18 | -18 | N/A |
12/31/2020 | 6 | -31 | -12 | -12 | N/A |
9/30/2020 | N/A | -31 | -21 | -21 | N/A |
6/30/2020 | N/A | -26 | -19 | -19 | N/A |
3/31/2020 | 3 | -24 | -20 | -20 | N/A |
12/31/2019 | 5 | -18 | -17 | -17 | N/A |
9/30/2019 | 6 | -65 | -21 | -21 | N/A |
6/30/2019 | 6 | -65 | -23 | -23 | N/A |
3/31/2019 | 3 | -72 | -23 | -23 | N/A |
12/31/2018 | 1 | -76 | -29 | -29 | N/A |
9/30/2018 | 40 | 6 | -58 | -57 | N/A |
6/30/2018 | 40 | -37 | -78 | -75 | N/A |
3/31/2018 | 40 | -64 | -94 | -90 | N/A |
12/31/2017 | 40 | -85 | -121 | -116 | N/A |
9/30/2017 | N/A | -138 | -101 | -98 | N/A |
6/30/2017 | N/A | -116 | -54 | -53 | N/A |
3/31/2017 | N/A | -101 | N/A | -54 | N/A |
12/31/2016 | N/A | -96 | N/A | -41 | N/A |
9/30/2016 | N/A | -94 | N/A | -38 | N/A |
6/30/2016 | N/A | -87 | N/A | -78 | N/A |
3/31/2016 | N/A | -84 | N/A | -70 | N/A |
12/31/2015 | N/A | -82 | N/A | -69 | N/A |
9/30/2015 | N/A | -78 | N/A | -64 | N/A |
6/30/2015 | N/A | -71 | N/A | -58 | N/A |
3/31/2015 | N/A | -60 | N/A | -54 | N/A |
12/31/2014 | N/A | -83 | N/A | -40 | N/A |
9/30/2014 | N/A | -73 | N/A | -33 | N/A |
6/30/2014 | N/A | -64 | N/A | -27 | N/A |
3/31/2014 | N/A | -59 | N/A | -18 | N/A |
12/31/2013 | N/A | -18 | N/A | -17 | N/A |
9/30/2013 | N/A | -17 | N/A | -17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARAV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ARAV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ARAV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ARAV's revenue is expected to decline over the next 3 years (-32.3% per year).
High Growth Revenue: ARAV's revenue is forecast to decline over the next 3 years (-32.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ARAV's Return on Equity is forecast to be high in 3 years time